Harmony Biosciences Holdings, Inc. $HRMY Shares Sold by Livforsakringsbolaget Skandia Omsesidigt

Livforsakringsbolaget Skandia Omsesidigt trimmed its position in shares of Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) by 79.4% during the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 10,600 shares of the company’s stock after selling 40,800 shares during the period. Livforsakringsbolaget Skandia Omsesidigt’s holdings in Harmony Biosciences were worth $396,000 as of its most recent SEC filing.

A number of other large investors also recently added to or reduced their stakes in the company. Dimensional Fund Advisors LP lifted its stake in Harmony Biosciences by 6.9% during the third quarter. Dimensional Fund Advisors LP now owns 1,691,581 shares of the company’s stock worth $46,620,000 after purchasing an additional 109,405 shares in the last quarter. American Century Companies Inc. lifted its stake in Harmony Biosciences by 11.2% during the third quarter. American Century Companies Inc. now owns 1,669,565 shares of the company’s stock worth $46,013,000 after purchasing an additional 168,145 shares in the last quarter. LSV Asset Management lifted its stake in Harmony Biosciences by 3.9% during the fourth quarter. LSV Asset Management now owns 1,657,093 shares of the company’s stock worth $62,008,000 after purchasing an additional 62,200 shares in the last quarter. Arrowstreet Capital Limited Partnership lifted its stake in Harmony Biosciences by 42.8% during the third quarter. Arrowstreet Capital Limited Partnership now owns 1,295,381 shares of the company’s stock worth $35,701,000 after purchasing an additional 388,472 shares in the last quarter. Finally, Geode Capital Management LLC lifted its stake in Harmony Biosciences by 1.0% during the fourth quarter. Geode Capital Management LLC now owns 1,270,586 shares of the company’s stock worth $47,551,000 after purchasing an additional 12,323 shares in the last quarter. 86.23% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

A number of research analysts have commented on the company. Needham & Company LLC decreased their price target on Harmony Biosciences from $46.00 to $44.00 and set a “buy” rating on the stock in a research note on Wednesday, February 25th. HC Wainwright restated a “buy” rating on shares of Harmony Biosciences in a research note on Friday, May 22nd. UBS Group cut their price objective on Harmony Biosciences from $46.00 to $36.00 and set a “neutral” rating on the stock in a research report on Wednesday, February 25th. Deutsche Bank Aktiengesellschaft lowered Harmony Biosciences from a “buy” rating to a “hold” rating and set a $31.00 price objective on the stock. in a research report on Monday, February 23rd. Finally, Wall Street Zen lowered Harmony Biosciences from a “buy” rating to a “hold” rating in a research report on Saturday, February 28th. Four analysts have rated the stock with a Buy rating, six have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and an average price target of $40.89.

Harmony Biosciences Stock Down 2.3%

Harmony Biosciences stock opened at $32.20 on Friday. Harmony Biosciences Holdings, Inc. has a twelve month low of $25.52 and a twelve month high of $40.87. The stock’s fifty day simple moving average is $30.16 and its 200-day simple moving average is $33.12. The company has a current ratio of 3.58, a quick ratio of 3.56 and a debt-to-equity ratio of 0.15. The firm has a market capitalization of $1.86 billion, a P/E ratio of 12.98, a P/E/G ratio of 0.23 and a beta of 0.96.

Harmony Biosciences (NASDAQ:HRMY) last posted its quarterly earnings data on Thursday, May 7th. The company reported $0.55 earnings per share for the quarter, missing analysts’ consensus estimates of $0.76 by ($0.21). Harmony Biosciences had a return on equity of 17.19% and a net margin of 16.20%.The company had revenue of $215.39 million for the quarter, compared to analysts’ expectations of $220.84 million. During the same period in the prior year, the company posted $0.78 EPS. The firm’s revenue was up 16.6% compared to the same quarter last year. As a group, equities analysts expect that Harmony Biosciences Holdings, Inc. will post 3.2 earnings per share for the current fiscal year.

Harmony Biosciences Company Profile

Harmony Biosciences Holdings, Inc is a commercial‐stage biopharmaceutical company focused on developing and delivering therapies for people with rare neurological and endocrine diseases. Founded in 2017 and headquartered in Plymouth Meeting, Pennsylvania, Harmony Biosciences went public in 2020 and trades on the Nasdaq under the ticker HRMY. The company’s mission centers on identifying and advancing medicines that address critical unmet needs in patient populations underserved by existing treatments.

The company’s flagship product is WAKIX (pitolisant), the first and only histamine H3 receptor antagonist/inverse agonist approved by the U.S.